BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim R, Kang TW, Cha DI, Song KD, Lee MW, Rhim H, Lim HK, Sinn DH. Percutaneous cryoablation for perivascular hepatocellular carcinoma: Therapeutic efficacy and vascular complications. Eur Radiol. 2018; Epub ahead of print. [PMID: 30043160 DOI: 10.1007/s00330-018-5617-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang K, Wang C, Jiang H, Zhang Y, Lin W, Mo J, Jin C. Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go. Front Immunol 2021;12:792781. [PMID: 34975896 DOI: 10.3389/fimmu.2021.792781] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zou ZM, Chang DH, Liu H, Xiao YD. Current updates in machine learning in the prediction of therapeutic outcome of hepatocellular carcinoma: what should we know? Insights Imaging 2021;12:31. [PMID: 33675433 DOI: 10.1186/s13244-021-00977-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Yang S, Lin H, Song J. Efficacy and safety of various primary treatment strategies for very early and early hepatocellular carcinoma: a network meta-analysis. Cancer Cell Int 2021;21:681. [PMID: 34923980 DOI: 10.1186/s12935-021-02365-1] [Reference Citation Analysis]
4 Xue J, Ni H, Wang F, Xu K, Niu M. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy. J Interv Med 2021;4:105-13. [PMID: 34805958 DOI: 10.1016/j.jimed.2021.05.002] [Reference Citation Analysis]
5 Luerken L, Haimerl M, Doppler M, Uller W, Beyer LP, Stroszczynski C, Einspieler I. Update on Percutaneous Local Ablative Procedures for the Treatment of Hepatocellular Carcinoma. Rofo 2022. [PMID: 35545102 DOI: 10.1055/a-1768-0954] [Reference Citation Analysis]
6 Ko SE, Lee MW, Rhim H, Kang TW, Song KD, Cha DI, Lim HK. Comparison of procedure-related complications between percutaneous cryoablation and radiofrequency ablation for treating periductal hepatocellular carcinoma. Int J Hyperthermia 2020;37:1354-61. [PMID: 33297809 DOI: 10.1080/02656736.2020.1849824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Shen Y, Wang H, Wei J, Li W. Early Prediction of Objective Response of Fibrinogen in a Real-World Cohort of Hepatocellular Carcinoma Cases Treated by Programmed Cell Death Receptor-1 and Lenvatinib. Onco Targets Ther 2021;14:5019-26. [PMID: 34675546 DOI: 10.2147/OTT.S332351] [Reference Citation Analysis]
8 Ma J, Wang F, Zhang W, Wang L, Yang X, Qian Y, Huang J, Wang J, Yang J. Percutaneous cryoablation for the treatment of liver cancer at special sites: an assessment of efficacy and safety. Quant Imaging Med Surg. 2019;9:1948-1957. [PMID: 31929967 DOI: 10.21037/qims.2019.11.12] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Kang TW, Lim HK, Cha DI. Percutaneous ablation for perivascular hepatocellular carcinoma: Refining the current status based on emerging evidence and future perspectives. World J Gastroenterol 2018; 24(47): 5331-5337 [PMID: 30598578 DOI: 10.3748/wjg.v24.i47.5331] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
10 Hinrichs JB, Wacker FK. [Locoregional and local ablative treatment options for liver tumors]. Internist (Berl) 2020;61:158-63. [PMID: 31919532 DOI: 10.1007/s00108-019-00725-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. [DOI: 10.1136/bmj.m3544] [Cited by in Crossref: 13] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
12 Lv X, Chen M, Kong C, Shu G, Meng M, Ye W, Cheng S, Zheng L, Fang S, Chen C, Wu F, Weng Q, Tu J, Zhao Z, Ji J. Construction of a novel radiomics nomogram for the prediction of aggressive intrasegmental recurrence of HCC after radiofrequency ablation. Eur J Radiol 2021;144:109955. [PMID: 34600237 DOI: 10.1016/j.ejrad.2021.109955] [Reference Citation Analysis]
13 Cha SY, Kang TW, Min JH, Song KD, Lee MW, Rhim H, Lim HK, Sinn DH, Park MS. RF Ablation Versus Cryoablation for Small Perivascular Hepatocellular Carcinoma: Propensity Score Analyses of Mid-Term Outcomes. Cardiovasc Intervent Radiol 2020;43:434-44. [PMID: 31844951 DOI: 10.1007/s00270-019-02394-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Ke S. Advances in the interventional therapy of hepatocellular carcinoma originating from the caudate lobe. Journal of Interventional Medicine 2022;5:51-6. [DOI: 10.1016/j.jimed.2022.03.002] [Reference Citation Analysis]
15 Wang F, Ma J, Wu L, Li N, Luo R, Wei G, Yang J. Percutaneous cryoablation of subcapsular hepatocellular carcinoma: a retrospective study of 57 cases. Diagn Interv Radiol 2020;26:34-9. [PMID: 31650975 DOI: 10.5152/dir.2019.18543] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Zhou Y, Yang Y, Zhou B, Wang Z, Zhu R, Chen X, Ouyang J, Li Q, Zhou J. Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria. J Hepatocell Carcinoma 2021;8:625-44. [PMID: 34189133 DOI: 10.2147/JHC.S298709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Yang P, Li N. Efficacy of percutaneous ethanol injection versus radiofrequency ablation for single hepatocellular carcinoma no larger than 5 cm. J Int Med Res 2022;50:3000605221111281. [PMID: 35861264 DOI: 10.1177/03000605221111281] [Reference Citation Analysis]
18 Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus 2021;13:e19274. [PMID: 34754704 DOI: 10.7759/cureus.19274] [Reference Citation Analysis]
19 Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:293-313. [PMID: 33510460 DOI: 10.1038/s41575-020-00395-0] [Cited by in Crossref: 98] [Cited by in F6Publishing: 78] [Article Influence: 98.0] [Reference Citation Analysis]
20 Zhang W, Gao X, Sun J, Cheng J, Hu Y, Dong Z, Kong H, Zhang H, Wang C, Yang Y. Percutaneous Argon-Helium Cryoablation for Small Hepatocellular Carcinoma Located Adjacent to a Major Organ or Viscus: A Retrospective Study of 92 Patients at a Single Center. Med Sci Monit 2021;27:e931473. [PMID: 34385410 DOI: 10.12659/MSM.931473] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]